← All trials
NCT03522246
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2018
- Primary completion
- Dec 30, 2024
- Completion date
- Dec 30, 2030
- First posted
- —
- Last posted
- —
- Enrollment
- 1012
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- pharmaandLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Foundation MedicineCollaborator
- Gynecologic Oncology GroupCollaborator
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.